Shares of Gilead Sciences Inc. GILD slipped 2.13% to $106.19 Monday, on what proved to be an all-around favorable trading ...

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...